{"id":33635,"date":"2025-05-27T14:16:30","date_gmt":"2025-05-27T12:16:30","guid":{"rendered":"https:\/\/ggba.swiss\/hedera-dx-raises-eur-15-million-to-expand-access-to-precision-cancer-care\/"},"modified":"2025-05-27T14:18:41","modified_gmt":"2025-05-27T12:18:41","slug":"hedera-dx-leve-eur-15-millions-pour-elargir-lacces-aux-soins-oncologiques-de-precision","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/hedera-dx-leve-eur-15-millions-pour-elargir-lacces-aux-soins-oncologiques-de-precision\/","title":{"rendered":"Hedera Dx l\u00e8ve EUR 15 millions pour \u00e9largir l&rsquo;acc\u00e8s aux soins oncologiques de pr\u00e9cision"},"content":{"rendered":"\n<p><a href=\"https:\/\/www.hederadx.com\/\">Hedera Dx<\/a>, une soci\u00e9t\u00e9 lausannoise sp\u00e9cialis\u00e9e dans l&rsquo;oncologie de pr\u00e9cision, a lev\u00e9 EUR 15 millions en s\u00e9rie A afin d&rsquo;\u00e9largir l&rsquo;acc\u00e8s mondial aux soins avanc\u00e9s contre le cancer. Ce financement permettra de soutenir l&rsquo;expansion commerciale de ses solutions de d\u00e9pistage du cancer par analyse sanguine et d&rsquo;am\u00e9liorer son infrastructure de donn\u00e9es r\u00e9elles.<\/p>\n\n\n\n<p>Fond\u00e9e en 2021 et bas\u00e9e au <a href=\"https:\/\/www.biopole.ch\/\">Biop\u00f4le<\/a> \u00e0 Lausanne, Hedera Dx s&rsquo;attaque \u00e0 un d\u00e9fi persistant en oncologie : l&rsquo;acc\u00e8s limit\u00e9 des patients aux th\u00e9rapies cibl\u00e9es en raison de mod\u00e8les de tests centralis\u00e9s. En dehors des \u00c9tats-Unis, o\u00f9 les diagnostics centralis\u00e9s dominent, de nombreux syst\u00e8mes de sant\u00e9 exigent que les tests soient effectu\u00e9s dans les laboratoires hospitaliers. Pour r\u00e9pondre \u00e0 ce besoin, Hedera Dx a d\u00e9velopp\u00e9 une solution de biopsie liquide rentable et \u00e9volutive qui permet aux h\u00f4pitaux d&rsquo;effectuer des diagnostics mol\u00e9culaires sur place.<\/p>\n\n\n\n<p>D\u00e9j\u00e0 d\u00e9ploy\u00e9e dans 11 pays europ\u00e9ens, la plateforme de biopsie liquide de la soci\u00e9t\u00e9 combine un profilage mol\u00e9culaire de haute qualit\u00e9 avec un moteur aliment\u00e9 par l&rsquo;IA qui g\u00e9n\u00e8re des informations centr\u00e9es sur le patient. Ces informations aident non seulement les m\u00e9decins \u00e0 prendre des d\u00e9cisions th\u00e9rapeutiques personnalis\u00e9es, mais elles permettent \u00e9galement aux partenaires biopharmaceutiques d&rsquo;acc\u00e9l\u00e9rer le d\u00e9veloppement de traitements oncologiques de nouvelle g\u00e9n\u00e9ration.<\/p>\n\n\n\n<p>Le tour de table de s\u00e9rie A a \u00e9t\u00e9 men\u00e9 par <a href=\"https:\/\/vsquared.vc\/\">Vsquared Ventures<\/a>, avec l&rsquo;arriv\u00e9e d&rsquo;un nouvel investisseur, <a href=\"https:\/\/tesi.fi\/en\/\">Tesi<\/a>, qui rejoint les investisseurs existants <a href=\"https:\/\/www.helsana.ch\/en\/helsana-group\/about-us\/healthinvest.html\">Helsana HealthInvest<\/a>, <a href=\"https:\/\/evm.is\/\">Eyrir Venture Management<\/a>, <a href=\"https:\/\/www.inventure.capital\/\">Inventure<\/a> et <a href=\"https:\/\/www.topharvest.be\/\">Top Harvest<\/a>. Ces fonds aideront Hedera Dx \u00e0 \u00e9tendre sa solution \u00e0 davantage de syst\u00e8mes de sant\u00e9 dans le monde et \u00e0 poursuivre son objectif de faire de l&rsquo;oncologie de pr\u00e9cision une offre standard.<\/p>\n\n\n\n<p>L&rsquo;\u00e9quipe de direction de Hedera Dx apporte une exp\u00e9rience approfondie acquise dans des entreprises telles que Blueprint Genetics, Roche et Molecular Health. La soci\u00e9t\u00e9 se positionne \u00e0 la crois\u00e9e du diagnostic et des donn\u00e9es r\u00e9elles, avec une vision \u00e0 long terme qui consiste \u00e0 devenir une plateforme mondiale pour l&rsquo;innovation en mati\u00e8re de soins contre le cancer.<\/p>\n\n\n\n<p>Gr\u00e2ce \u00e0 ce nouvel investissement, Hedera Dx acc\u00e9l\u00e8re sa mission visant \u00e0 \u00e9liminer les obstacles structurels en oncologie, afin de permettre \u00e0 un plus grand nombre de patients d&rsquo;acc\u00e9der \u00e0 des traitements cibl\u00e9s qui peuvent leur sauver la vie.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hedera Dx a lev\u00e9 EUR 15 millions pour d\u00e9velopper ses diagnostics oncologiques en milieu hospitalier et rendre l&rsquo;oncologie de pr\u00e9cision plus accessible aux patients du monde entier.<\/p>\n","protected":false},"author":6,"featured_media":33632,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1179,1169,1148,1188,1140,1168],"class_list":["post-33635","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-artificial-intelligence-fr-2","tag-biotech-fr-2","tag-financing-fr-2","tag-healthcare-fr-2","tag-oncology-fr-2","tag-technology-park-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Hedera Dx l\u00e8ve EUR 15 millions | GGBa<\/title>\n<meta name=\"description\" content=\"La soci\u00e9t\u00e9 lausannoise Hedera Dx a lev\u00e9 EUR 15 millions pour d\u00e9velopper ses diagnostics oncologiques en milieu hospitalier.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/hedera-dx-leve-eur-15-millions-pour-elargir-lacces-aux-soins-oncologiques-de-precision\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hedera Dx l\u00e8ve EUR 15 millions | GGBa\" \/>\n<meta property=\"og:description\" content=\"La soci\u00e9t\u00e9 lausannoise Hedera Dx a lev\u00e9 EUR 15 millions pour d\u00e9velopper ses diagnostics oncologiques en milieu hospitalier.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/hedera-dx-leve-eur-15-millions-pour-elargir-lacces-aux-soins-oncologiques-de-precision\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-27T12:16:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-27T12:18:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/Hedera-Tumor-1180x811-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/hedera-dx-leve-eur-15-millions-pour-elargir-lacces-aux-soins-oncologiques-de-precision\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/hedera-dx-leve-eur-15-millions-pour-elargir-lacces-aux-soins-oncologiques-de-precision\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Hedera Dx l\u00e8ve EUR 15 millions pour \u00e9largir l&rsquo;acc\u00e8s aux soins oncologiques de pr\u00e9cision\",\"datePublished\":\"2025-05-27T12:16:30+00:00\",\"dateModified\":\"2025-05-27T12:18:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/hedera-dx-leve-eur-15-millions-pour-elargir-lacces-aux-soins-oncologiques-de-precision\/\"},\"wordCount\":436,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/hedera-dx-leve-eur-15-millions-pour-elargir-lacces-aux-soins-oncologiques-de-precision\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/Hedera-Tumor-1180x811-1.jpg\",\"keywords\":[\"Artificial Intelligence\",\"Biotech\",\"Financing\",\"Healthcare\",\"Oncology\",\"Technology Park\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/hedera-dx-leve-eur-15-millions-pour-elargir-lacces-aux-soins-oncologiques-de-precision\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/hedera-dx-leve-eur-15-millions-pour-elargir-lacces-aux-soins-oncologiques-de-precision\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/hedera-dx-leve-eur-15-millions-pour-elargir-lacces-aux-soins-oncologiques-de-precision\/\",\"name\":\"Hedera Dx l\u00e8ve EUR 15 millions | GGBa\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/hedera-dx-leve-eur-15-millions-pour-elargir-lacces-aux-soins-oncologiques-de-precision\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/hedera-dx-leve-eur-15-millions-pour-elargir-lacces-aux-soins-oncologiques-de-precision\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/Hedera-Tumor-1180x811-1.jpg\",\"datePublished\":\"2025-05-27T12:16:30+00:00\",\"dateModified\":\"2025-05-27T12:18:41+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"La soci\u00e9t\u00e9 lausannoise Hedera Dx a lev\u00e9 EUR 15 millions pour d\u00e9velopper ses diagnostics oncologiques en milieu hospitalier.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/hedera-dx-leve-eur-15-millions-pour-elargir-lacces-aux-soins-oncologiques-de-precision\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/hedera-dx-leve-eur-15-millions-pour-elargir-lacces-aux-soins-oncologiques-de-precision\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/hedera-dx-leve-eur-15-millions-pour-elargir-lacces-aux-soins-oncologiques-de-precision\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/Hedera-Tumor-1180x811-1.jpg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/Hedera-Tumor-1180x811-1.jpg\",\"width\":1180,\"height\":811,\"caption\":\"Hedera Dx fournit aux laboratoires hospitaliers des diagnostics par biopsie liquide et des informations bas\u00e9es sur l'intelligence artificielle afin d'am\u00e9liorer l'acc\u00e8s aux th\u00e9rapies cibl\u00e9es contre le cancer. | \u00a9 Hedera Dx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/hedera-dx-leve-eur-15-millions-pour-elargir-lacces-aux-soins-oncologiques-de-precision\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hedera Dx l\u00e8ve EUR 15 millions pour \u00e9largir l&#8217;acc\u00e8s aux soins oncologiques de pr\u00e9cision\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Hedera Dx l\u00e8ve EUR 15 millions | GGBa","description":"La soci\u00e9t\u00e9 lausannoise Hedera Dx a lev\u00e9 EUR 15 millions pour d\u00e9velopper ses diagnostics oncologiques en milieu hospitalier.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/hedera-dx-leve-eur-15-millions-pour-elargir-lacces-aux-soins-oncologiques-de-precision\/","og_locale":"fr_FR","og_type":"article","og_title":"Hedera Dx l\u00e8ve EUR 15 millions | GGBa","og_description":"La soci\u00e9t\u00e9 lausannoise Hedera Dx a lev\u00e9 EUR 15 millions pour d\u00e9velopper ses diagnostics oncologiques en milieu hospitalier.","og_url":"https:\/\/ggba.swiss\/fr\/hedera-dx-leve-eur-15-millions-pour-elargir-lacces-aux-soins-oncologiques-de-precision\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2025-05-27T12:16:30+00:00","article_modified_time":"2025-05-27T12:18:41+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/Hedera-Tumor-1180x811-1.jpg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/hedera-dx-leve-eur-15-millions-pour-elargir-lacces-aux-soins-oncologiques-de-precision\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/hedera-dx-leve-eur-15-millions-pour-elargir-lacces-aux-soins-oncologiques-de-precision\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Hedera Dx l\u00e8ve EUR 15 millions pour \u00e9largir l&rsquo;acc\u00e8s aux soins oncologiques de pr\u00e9cision","datePublished":"2025-05-27T12:16:30+00:00","dateModified":"2025-05-27T12:18:41+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/hedera-dx-leve-eur-15-millions-pour-elargir-lacces-aux-soins-oncologiques-de-precision\/"},"wordCount":436,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/hedera-dx-leve-eur-15-millions-pour-elargir-lacces-aux-soins-oncologiques-de-precision\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/Hedera-Tumor-1180x811-1.jpg","keywords":["Artificial Intelligence","Biotech","Financing","Healthcare","Oncology","Technology Park"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/hedera-dx-leve-eur-15-millions-pour-elargir-lacces-aux-soins-oncologiques-de-precision\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/hedera-dx-leve-eur-15-millions-pour-elargir-lacces-aux-soins-oncologiques-de-precision\/","url":"https:\/\/ggba.swiss\/fr\/hedera-dx-leve-eur-15-millions-pour-elargir-lacces-aux-soins-oncologiques-de-precision\/","name":"Hedera Dx l\u00e8ve EUR 15 millions | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/hedera-dx-leve-eur-15-millions-pour-elargir-lacces-aux-soins-oncologiques-de-precision\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/hedera-dx-leve-eur-15-millions-pour-elargir-lacces-aux-soins-oncologiques-de-precision\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/Hedera-Tumor-1180x811-1.jpg","datePublished":"2025-05-27T12:16:30+00:00","dateModified":"2025-05-27T12:18:41+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"La soci\u00e9t\u00e9 lausannoise Hedera Dx a lev\u00e9 EUR 15 millions pour d\u00e9velopper ses diagnostics oncologiques en milieu hospitalier.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/hedera-dx-leve-eur-15-millions-pour-elargir-lacces-aux-soins-oncologiques-de-precision\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/hedera-dx-leve-eur-15-millions-pour-elargir-lacces-aux-soins-oncologiques-de-precision\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/hedera-dx-leve-eur-15-millions-pour-elargir-lacces-aux-soins-oncologiques-de-precision\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/Hedera-Tumor-1180x811-1.jpg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/Hedera-Tumor-1180x811-1.jpg","width":1180,"height":811,"caption":"Hedera Dx fournit aux laboratoires hospitaliers des diagnostics par biopsie liquide et des informations bas\u00e9es sur l'intelligence artificielle afin d'am\u00e9liorer l'acc\u00e8s aux th\u00e9rapies cibl\u00e9es contre le cancer. | \u00a9 Hedera Dx"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/hedera-dx-leve-eur-15-millions-pour-elargir-lacces-aux-soins-oncologiques-de-precision\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"Hedera Dx l\u00e8ve EUR 15 millions pour \u00e9largir l&#8217;acc\u00e8s aux soins oncologiques de pr\u00e9cision"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/33635","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=33635"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/33635\/revisions"}],"predecessor-version":[{"id":33637,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/33635\/revisions\/33637"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/33632"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=33635"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=33635"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=33635"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}